Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Health Technology Assessment: how do we define best practice...

Alicia Granados of Genzyme speaks with pharmaphorum about how the health technology assessment space has evolved throughout her career and where she thinks it is heading. The growing importance of Health Technology Assessments (HTAs) in reimbursement decision-making cannot be...

Articles

Pharma news highlights: Eli Lilly, Abbott and more

Ed Silverman shares his news highlights from the past few weeks, which includes an incorrect CV, a lawsuit over male breasts and an alleged over-hyped clinical study. The past month may have marked the end of summer, but there was no shortage of interesting affairs in...

Articles

Physician perspectives: Bryan Vartabedian

This month we speak with American paediatric gastroenterologist, Bryan Vartabedian, on how social media has revolutionised the pharma industry. Continuing our physician perspectives series, where we interview healthcare professionals about how the...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital